Perrigo launches testosterone gel 1%

DUBLIN — Perrigo Co. on Monday announced the launch of testosterone gel 1%, the therapeutic equivalent to Androgel 1% from AbbVie. The gel is used to treat males who have low or no testosterone. Annual sales of the medication were greater than $300 million, according to data from Symphony Health Solutions. 

 

"We are very pleased to launch an AB equivalent testosterone 1.0% product. It occurred as a result of a strong effort by our research and development and the entire Rx team," said Joseph Papa, Perrigo's chairman, president and CEO. "This highlights our commitment to bringing quality affordable healthcare products to the market."